MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder

•MOG antibody disease is the most recent antigen specific autoimmune disease on the NMO Spectrum.•MOG antibody disease is characterized by optic neuritis and less commonly transverse myelitis with generally better outcomes compared to the AQP4 NMO.•Half of MOG antibody positive cases remain monophas...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Multiple sclerosis and related disorders Ročník 25; s. 66 - 72
Hlavní autoři: Narayan, Ram, Simpson, Alexandra, Fritsche, Katelyn, Salama, Sara, Pardo, Santiago, Mealy, Maureen, Paul, Friedemann, Levy, Michael
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.10.2018
Témata:
Animals
Autoantibodies - blood
Humans
Myelin-Oligodendrocyte Glycoprotein - immunology
Neurology
Neuromyelitis Optica - blood
Neuromyelitis Optica - immunology
ISSN:2211-0348, 2211-0356, 2211-0356
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:•MOG antibody disease is the most recent antigen specific autoimmune disease on the NMO Spectrum.•MOG antibody disease is characterized by optic neuritis and less commonly transverse myelitis with generally better outcomes compared to the AQP4 NMO.•Half of MOG antibody positive cases remain monophasic after the initial attack. MOG antibody disease is an autoimmune disease of the central nervous system associated with a serological antibody against MOG, myelin oligodendrocyte glycoprotein. MOG is a glycoprotein expressed on the outer membrane of myelin and solely found within the central nervous system, including in the brain, optic nerves and spinal cord. Clinically, the disease resembles neuromyelitis optica spectrum disorders in the predilection for relapses of optic neuritis and transverse myelitis. In addition, acute disseminated encephalomyelitis (ADEM) is a well-recognized phenotype of MOG antibody disease in children. In recent studies around the world where MOG testing is available, up to 42% of NMOSD patients who test seronegative for the AQP4 antibody test positive for MOG antibodies. MOG antibody disease has thus recently emerged as a distinct entity carved out of the patient population diagnosed with NMOSD. In this review, we examine the history of the MOG antibody and its relevance to demyelinating disease, as well as compare the clinical, radiographic and serological profiles of patients with MOG antibody with patients with AQP4 antibody.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2211-0348
2211-0356
2211-0356
DOI:10.1016/j.msard.2018.07.025